Viewing molecular mechanisms of ageing through a lens

Ageing Research Reviews

Volumn 1, Issue 3, 2002, Pages 465-479

  Harding, John J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Crystallin; Ageing; Cataract; Conformational disease; Post translational modification of proteins; Unfolding

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA CRYSTALLIN; AMYLOID; AMYLOID PROTEIN; CHAPERONE; CRYSTALLIN; IBUPROFEN; LENS PROTEIN; PARACETAMOL; POLYPEPTIDE; TAU PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGING; ALEXANDER DISEASE; ALZHEIMER DISEASE; AMYLOIDOSIS; BOVINE SPONGIFORM ENCEPHALOPATHY; CATARACT; CATARACT EXTRACTION; CATARACTOGENESIS; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; CREUTZFELDT JAKOB DISEASE; DOWN SYNDROME; DRUG EFFECT; ENZYME INACTIVATION; GLYCATION; HUMAN; HUNTINGTON CHOREA; LENS; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; ANIMAL; CELL AGING; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN FOLDING;

AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CATARACT; CELL AGING; CRYSTALLINS; HUMANS; LENS, CRYSTALLINE; MOLECULAR CHAPERONES; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 0036597985     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-1637(02)00012-0     Document Type: Review

References (53)

1. Age-related Eye Disease Study, 2001. Risk factors associated with age-related nuclear and cortical cataract. Ophthalmol. 108, 1400-1408.
2. Anthony J.C., Breitner J.C.S., Zandi P.P.et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists. Neurology. 54:2000;2066-2071.
3. Antiplatelet Triallists' Collaboration, 1988. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br. Med. J. 296, 320-331.
4. Bax B., Lapatto R., Nalini V., Driessen H., Lindley P.F., Mahadevan D., Blundell T.L., Slingsby C. X-ray analysis of βB2-crystallin and evolution of the oligomeric lens proteins. Nature. 347:1990;776-780.
5. Beswick H.T., Harding J.J. Conformational changes induced in lens α- and γ- crystallins by modification with glucose 6-phosphate. Implications for cataract. Biochem. J. 246:1987;761-769.
6. Blakytny R., Harding J.J. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp. Eye Res. 54:1992;509-518.
7. Brion J.P., Hanger D.P., Bruce M.T., Couck A.M., Flament-Durand J., Anderton B.H. Tau in Alzheimer neurofibrillary tangles. Biochem. J. 273:1991;127-133.
8. Carrell R.W., Lomas D.A. Conformational disease. Lancet. 350:1997;134-138.
9. Cerami A., Vlassara H., Brownlee M. Glucose and ageing. Sci. Am. 255:1987;90-96.
10. Christen W.G., Manson J.E., Glynn R.J.et al. Low-dose aspirin and risk of cataract and subtypes in a randomised trial of US physicians. Ophthal. Epidemiol. 5:1998;133-142.
11. Clark J.I., Carper D. Phase separation in lens cytoplasm is genetically linked to cataract formation in the Philly mouse. Proc. Natl. Acad. Sci. U.S.A. 84:1987;122-125.
12. Derham B.K., Harding J.J. α-Crystallin as a molecular chaperone. Prog. Retinal Eye Res. 18:1999;463-509.
13. Diener H.C. Aspirin in the prevention of strokes. Biomed. Pharmacother. 53:1999;309-311.
14. Farahbakhsh Z.T., Huang Q.-L., Ding L.-L., Altenbach C., Steinhoff H.-J., Horwitz J., Hubbell W.L. Interaction of α-crystallin with spin-labelled peptides. Biochemistry. 34:1995;509-516.
15. Finch C.E., Cohen D.M. Aging, Metabolism and Alzheimer disease: review and hypotheses. Exp. Neurol. 143:1997;82-102.
16. Ganea E., Harding J.J. Molecular chaperones protect against glycation-induced inactivation of glucose 6-phosphate dehydrogenase. Eur. J. Biochem. 231:1995;181-185.
17. Ganea E., Harding J.J. Inhibition of 6-phosphogluconate dehydrogenase by carbamylation and protection by α-crystallin, a chaperone-like protein. Biochem. Biophys. Res. Commun. 222:1996;626-631.
18. Haley D.A., Horwitz J., Stewart P.L. The small heat-shock protein, αB-crystallin, has a variable quaternary structure. J. Mol. Biol. 277:1998;27-35.
19. Harding J.J. Conformational changes in human lens proteins in cataract. Biochem. J. 129:1972;97-100.
20. Harding J.J. Nonenzymatic posttranslational modification of proteins in vivo. Adv. Protein Chem. 37:1985;247-334.
21. Harding, J.J., 1991. Cataract: Biochemistry, Epidemiology and Pharmacology. Chapman & Hall, London.
22. Harding J.J. Pathophysiology of cataract. Curr. Opin. Ophthalmol. 4:1993;14-21.
23. Harding J.J. Estrogens and cataract. Arch. Ophthalmol. 112:1994;1511.
24. Harding J.J. Can drugs or micronutrients prevent cataract? Drugs Ageing. 18:2001;473-486.
25. Harding J.J., Egerton M., Harding R.S. Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol. 67:1989;518-524.
26. Heath M.M., Rixon K.C., Harding J.J. Glycation-induced inactivation of malate dehydrogenase: protection by aspirin and a lens molecular chaperone, alpha-crystallin. Biochim. Biophys. Acta. 1315:1996;176-184.
27. Hook D.W.A., Harding J.J. Alpha-crystallin acting as a molecular chaperone protects catalase against steroid-induced inactivation. FEBS Lett. 382:1996;281-284.
28. Hook D.W.A., Harding J.J. Protection of enzymes by α-crystallin acting as a molecular chaperone. Int. J. Biol. Macromol. 22:1998;295-306.
29. Jacob H.S., Brain M.C., Dacie J.V., Carrell R.W., Lehmann H. Abnormal haem binding and globin SH group blockade in unstable haemoglobins. Nature. 218:1968;1214-1217.
30. Janne P.A., Mayer R.J. Chemoprevention of colorectal cancer. New Engl. J. Med. 342:2000;1960-1968.
31. Kawas C., Resnick S., Morrison A., Brookmeyer R., Corrada M., Zonderman A., Bacal C., Lingle D.D., Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology. 48:1997;1517-1521.
32. Klein B.E.K., Klein R., Ritter L.L. Is there evidence of an estrogen effect on age-related lens opacities? Arch. Ophthalmol. 112:1994;85-91.
33. Klein B.E.K., Klein R., Lee K.E., Danforth L.G. Drug use and five-year incidence of age-related cataracts. Ophthalmology. 108:2001;1670-1674.
34. Levi M.S., Borne R.F., Williamson J.S. A review of cancer chemopreventive agents. Curr. Med. Chem. 8:2001;1349-1362.
35. Lindner R.A., Treweek T.M., Carver J.A. The molecular chaperone α-crystallin is in kinetic competition with aggregation to stabilise a monomeric molten-globule form of α-lactalbumin. Biochem. J. 354:2001;79-87.
36. Minassian D.C., Mehra V. 3.8 Million blinded by cataract each year: projections from the first epidemiological study of incidence of cataract blindness in India. Brit. J. Ophthalmol. 74:1990;341-343.
37. Mohan M., Sperduto R.D., Surander K.A.et al. India-US case-control study of age-related cataracts. Arch. Ophthalmol. 107:1989;670-676.
38. Nelson J.E., Harris R.E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol. Rep. 7:2000;169-170.
39. Paterson J.R., Lawrence J.R. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. Q. J. Med. 94:2001;445-448.
40. Raza K., Harding J.J. Non-enzymic modification of lens proteins by glucose and fructose: effects of ibuprofen. Exp. Eye Res. 52:1991;205-212.
41. Rigas B., Shiff S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med. Hypotheses. 54:2000;210-215.
42. Robinson A.B., Rudd C.J. Deamidation of glutaminyl and asparaginyl residues in peptides and proteins. Curr. Top. Cell Regulation. 8:1974;247-295.
43. Sohrabji F., Miranda R.C. Hormone replacement: therapeutic strategies in the treatment of Alzheimer's disease and ageing-related cognitive disorders. Expert Opin. Ther. Pat. 7:1997;611-629.
44. Stevens V.J., Rouzer C.A., Monnier V.M., Cerami A. Diabetic cataract formation: potential role of glycosylation of lens crystallins. Proc. Natl. Acad. Sci. U.S.A. 75:1978;2918-2922.
45. Swamy M.S., Abraham E.C. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 30:1989;1120-1126.
46. van Heyningen, Harding, J.J., 1986. Do aspirin-like analgesics protect against cataract? Lancet 1, 1111-1113.
47. Vicart P., Caron A., Guicheney P., Li Z., Prevost M., Faure A., Chateau D., Chapon F., Tome F., Dupret J., Fardeau M. A missense mutation in the αB-crystallin gene causes a desmin-related myopathy. Nat. Genet. 20:1998;92-95.
48. Vitek M.P., Bhattacharya K., Glendening M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation endproducts contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91:1994;4766-4770.
49. Wang J.Z., Grundke-Iqbal I., Iqbal K. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat. Med. 2:1996;871-875.
50. West S.K., Munoz B.E., Newland H.S. Lack of evidence for aspirin use and prevention of cataracts. Arch. Ophthalmol. 105:1987;1229-1231.
51. Wistow G., Turnell B., Summers L., Slingsby C., Moss D., Miller L., Lindley P., Blundell T. X-ray analysis of the eye lens protein γII-crystallin at 1.9 A resolution. J. Mol. Biol. 170:1983;175-202.
52. Yan S.-D., Chen X., Schmidt A.-M., Brett J., Godman G., Zou Y.-S., Scott C.W., Caputo C., Frappier T., Smith M.A., Perry G., Yen S.-H., Stern D. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. U.S.A. 91:1994;7787-7791.
53. Zhou X.M., Chun B., Wong Y., Fan X.M., Zhang H.B., Lin M.C.M., Kung H.F., Fan D.M., Lam S.K. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis. 22:2001;1393-1397.